Jonathan Montagu

Jonathan Montagu is the co-founder and CEO of HotSpot Therapeutics, a Boston biotech he started in 2017 to chase what the industry long called undruggable. His bet: target the 'natural hotspots' that evolution built into proteins to switch them on and off, and you can make small-molecule medicines with precision the old playbook couldn't reach. A chemist trained at Oxford, Scripps and Cancer Research UK with a Stanford MBA, he previously did the dealmaking that put Nimbus Therapeutics and Concert Pharmaceuticals on the map, including a $1B GSK transaction. Under him HotSpot has raised roughly $210M and pushed its Smart Allostery platform into the clinic, presenting first-in-human Phase 1 data on its CBL-B inhibitor HST-1011 at ESMO 2024.